Overview

Biomaterials are substances that treat, augment, or replace tissue, organs or body functions and are used regularly as components and elements in a wide variety of resorbable or permanent implants. Advances in materials technology and a better understanding of the biological processes involved in tissue formation and remodeling have led to the introduction of resorbable biomaterials-based products to address long-standing deficiencies of traditional products and therapies. Kensey Nash Corporation (KNC) has vast experience with developing biomaterial implants that harness the body’s inherent ability to repair tissue damage caused by disease, trauma or age.

KNC participates in the biomaterials market in several ways. We manufacture OEM finished products that are distributed by our customers into the marketplace. KNC also manufactures both proprietary and OEM biomaterial components for customers who incorporate them into their own products. Finally, we independently (or collaboratively) design and develop proprietary biomaterial products that are distributed to the marketplace by our strategic partners.

Our current biomaterials development programs encompass products for soft tissue repair, spine and trauma, orthobiologics and drug/device combinations. Several of our development programs address markets for which there are significant unmet clinical needs. These include cartilage regeneration, small diameter arterial substitution, tissue reinforcement and repair and controlled release drug delivery.